BR9612381A - Antagonistas receptores vitronectina - Google Patents

Antagonistas receptores vitronectina

Info

Publication number
BR9612381A
BR9612381A BR9612381A BR9612381A BR9612381A BR 9612381 A BR9612381 A BR 9612381A BR 9612381 A BR9612381 A BR 9612381A BR 9612381 A BR9612381 A BR 9612381A BR 9612381 A BR9612381 A BR 9612381A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
BR9612381A
Other languages
English (en)
Portuguese (pt)
Inventor
William E Bondinell
Richard M Keenan
Thomas Wen Fu Ku
William H Miller
James Samanen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9612381A publication Critical patent/BR9612381A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
BR9612381A 1995-12-29 1996-12-20 Antagonistas receptores vitronectina BR9612381A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US936795P 1995-12-29 1995-12-29
PCT/US1996/020327 WO1997024124A1 (en) 1995-12-29 1996-12-20 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
BR9612381A true BR9612381A (pt) 1999-07-13

Family

ID=21737218

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9612381A BR9612381A (pt) 1995-12-29 1996-12-20 Antagonistas receptores vitronectina

Country Status (14)

Country Link
US (1) US6159964A (cg-RX-API-DMAC7.html)
EP (1) EP0906103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2000502704A (cg-RX-API-DMAC7.html)
KR (1) KR19990076877A (cg-RX-API-DMAC7.html)
CN (1) CN1209063A (cg-RX-API-DMAC7.html)
AU (1) AU1295597A (cg-RX-API-DMAC7.html)
BR (1) BR9612381A (cg-RX-API-DMAC7.html)
CZ (1) CZ203898A3 (cg-RX-API-DMAC7.html)
IL (1) IL125030A0 (cg-RX-API-DMAC7.html)
NO (1) NO983001L (cg-RX-API-DMAC7.html)
PL (1) PL327626A1 (cg-RX-API-DMAC7.html)
TR (1) TR199801254T2 (cg-RX-API-DMAC7.html)
WO (1) WO1997024124A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9610854B (cg-RX-API-DMAC7.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006087A1 (en) * 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds
TR199801255T2 (xx) * 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r antagonistleri.
WO1997037655A1 (en) * 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
EP1000031A4 (en) * 1997-07-25 2001-08-16 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
AU736026B2 (en) * 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
AR015241A1 (es) * 1998-03-10 2001-04-18 Smithkline Beecham Corp Antagonistas del receptor de vitronectina composicion farmaceutica que los contiene, procedimiento para su preparacion y su empleo para la fabricacion deun medicamento.
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
SE9803773D0 (sv) * 1998-11-05 1998-11-05 Astra Pharma Prod Compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
DE50007899D1 (de) * 1999-02-20 2004-10-28 Merck Patent Gmbh Beta-alaninderivate
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
WO2001007036A1 (en) 1999-07-21 2001-02-01 American Home Products Corporation BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN
DE19939980A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
GB9929988D0 (en) * 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
ATE375330T1 (de) 2000-04-17 2007-10-15 Ucb Pharma Sa Enamin-derivate als zell-adhäsionsmoleküle
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
DE10028402A1 (de) * 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
WO2002004426A1 (en) 2000-07-07 2002-01-17 Celltech R & D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
US20040058915A1 (en) * 2000-08-29 2004-03-25 Khanna Ish Kumar Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
AU2001288515A1 (en) * 2000-08-30 2002-03-13 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
US6531494B1 (en) * 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6472372B1 (en) 2000-12-06 2002-10-29 Ortho-Mcneil Pharmaceuticals, Inc. 6-O-Carbamoyl ketolide antibacterials
KR100376088B1 (ko) * 2001-03-09 2003-03-28 주식회사 태평양 3-아미노프로필코질포스페이트 및 그의 염을 함유한미백화장료 조성물
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とTNFαとを用いる組合せ療法
JP4750360B2 (ja) 2001-10-22 2011-08-17 ザ スクリプス リサーチ インスティチュート 抗体ターゲッティング化合物
IL162292A0 (en) 2001-12-05 2005-11-20 Ortho Mcneil Pharm Inc 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials
GB0130341D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
JP4809227B2 (ja) 2003-09-26 2011-11-09 メルク セローノ ソシエテ アノニム タンパク質の産生に使用するためのリーダー配列
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
JP2009522295A (ja) * 2005-12-30 2009-06-11 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド 置換ビス−アミドメタロプロテアーゼ阻害剤
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
BRPI0806596A2 (pt) 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
WO2009061448A2 (en) 2007-11-08 2009-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
KR20120034666A (ko) 2009-05-22 2012-04-12 엑셀리시스, 인코포레이티드 증식성 질환에 대한 벤족사제핀 기반 p13k/mt0r의 억제제
BRPI1011206A2 (pt) 2009-05-25 2016-03-15 Merck Patent Gmbh administração contínua de ligantes de integrina para tratar câncer
RU2016146826A (ru) 2014-05-30 2018-07-04 Пфайзер Инк. Производные карбонитрилов как селективные модуляторы андрогенового рецептора
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
US10975056B2 (en) 2016-06-13 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of DNMT1
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
KR102605460B1 (ko) * 2017-02-28 2023-11-22 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
CN112805001B (zh) 2018-08-29 2024-07-23 莫菲克医疗股份有限公司 抑制αvβ6整联蛋白
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450707A (en) * 1966-12-13 1969-06-17 Sterling Drug Inc Certain 2-anilino-pyridine derivatives
US3627754A (en) * 1970-05-13 1971-12-14 Hoffmann La Roche Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
ZA9610853B (en) * 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.

Also Published As

Publication number Publication date
IL125030A0 (en) 1999-01-26
NO983001L (no) 1998-08-26
NO983001D0 (no) 1998-06-26
TR199801254T2 (xx) 1998-10-21
EP0906103A4 (cg-RX-API-DMAC7.html) 1999-04-07
AU1295597A (en) 1997-07-28
KR19990076877A (ko) 1999-10-25
CZ203898A3 (cs) 1999-03-17
JP2000502704A (ja) 2000-03-07
WO1997024124A1 (en) 1997-07-10
US6159964A (en) 2000-12-12
ZA9610854B (en) 1998-04-02
EP0906103A1 (en) 1999-04-07
CN1209063A (zh) 1999-02-24
PL327626A1 (en) 1998-12-21

Similar Documents

Publication Publication Date Title
NO983001D0 (no) Vitronectin-reseptor-antagonister
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO972016D0 (no) Indolyl-Y-reseptorantagonister
DK0957917T3 (da) Vitronectinreceptorantagonister
NO983737D0 (no) IL-8 reseptor antagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
FI960953L (fi) Endoteliinireseptoriantagonisteja
EP0810994A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
EP0866705A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
DK0741133T3 (da) Adhæsionsreceptorantagonister
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20001515D0 (no) Vitronektin reseptor-antagonist
NO20004503L (no) Vitronectin-reseptor-antagonister
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
DE69636597D1 (de) Endothelin rezeptor antagonisten
DE69616364D1 (de) Endothelinrezeptorantagonisten
NO20010620D0 (no) Vitronektinreseptor-antagonister
BR9603432A (pt) Antagonistas de receptores de endotelina
EP0812196A4 (en) ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]